Obesity drugs regulate neural systems to curb appetite, research reveals
A recent Northwestern Medicine study has identified novel neural circuits modulated by the diabetes and obesity-management drugs semaglutide and tirzepatide that help suppress appetite, according to findings published in The Journal of Clinical Investigation.
GLP-1 prescription rate relatively flat: Study
GLP-1 prescribing in the US may have reached a plateau, new data suggests. Prescribing rates remained stable from June to September, according to an analysis of EHR data from researchers at Truveta — a platform that includes de-identified patient data from more than 900 hospitals to support medical research advancements. In June, the overall prescribing […]
Weight loss drugs: Semaglutide boosts heart health regardless of how much weight patients lose, study suggests
The cardiovascular benefits of weight loss drug semaglutide (Ozempic, Wegovy) occur regardless of how much weight a person loses or their starting body weight, new analysis suggests.1Study authors said the findings indicate many more people could benefit from taking the glucagon-like peptide-1 (GLP-1) receptor agonist and current restrictions based on body mass index (BMI) thresholds […]
New potential therapeutic targets of metabolic disorder-associated kidney disease and diabetic kidney disease
Individuals with metabolic syndrome are at an increased risk of developing chronic kidney disease (CKD) or accelerating the progression of pre-existing CKD. Further, such individuals are predisposed to developing diabetes mellitus, increasing their susceptibility to diabetic kidney disease (DKD). Current DKD treatments have expanded to include renin-angiotensin-aldosterone system (RAAS) inhibitors, sodium-glucose cotransporter-2 (SGLT2) inhibitors, non-steroidal […]
Antidiabetic agents and dementia risk in type 2 diabetes: A systematic review and network meta‐analysis
Abstract Aims Certain antidiabetic agents may prevent dementia in patients with type 2 diabetes mellitus (T2DM). The purpose of this study is to elucidate the relative effect of antidiabetic agents on reducing dementia risk in patients with T2DM. Materials and Methods PubMed, Cochrane Library and Igaku Chuo Zasshi-Web from inception to 31 December 2023 were […]
With 60,000+ members, SheMed raises €43 million to advance personalised women’s healthcare in the UK
SheMed, London’s female-founded HealthTech company changing how women access personalised healthcare, today announced it has raised €43 million to further develop its innovative health platform and advance new breakthroughs for preemptive healthcare. The new funding will be used to expand SheMed’s UK operations, scaling its medical and technology teams, strengthening clinical infrastructure and enhancing its […]
GLP-1 Medicines From Metabolic Agents to Multi System Therapeutics
GLP-1 Medicines From Metabolic Agents to Multi System Therapeutics
Blood Thinners & Anti-Obesity Shots Dominate Medicare Drug Spending
Blood Thinners & Anti-Obesity Shots Dominate Medicare Drug Spending From diabetes injectables to blockbuster blood thinners, a handful of drugs account for a sizable share of Medicare’s pharmacy bill. This visualization, via Visual Capitalist’s Pallavi Rao, ranks the most common drugs by total Medicare spending in 2023, sourced from Centers for Medicare & Medicaid Services It tracks every […]
A MARKETING BOON FOR GLP-1 DRUGS: “Astounding” – 70% of Americans Have Obesity by New, More A
A MARKETING BOON FOR GLP-1 DRUGS: “Astounding” – 70% of Americans Have Obesity by New, More Accurate Definition. Weirdly, more people need blood pressure drugs under the new high blood pressure definition, and more people need diabetes drugs under the new blood sugar guidelines.
Novo Nordisk A/S (NVO): A Bull Case Theory
We came across a bullish thesis on Novo Nordisk A/S on The Analyst’s Journal’s Substack by A_Capital. In this article, we will summarize the bulls’ thesis on NVO. Novo Nordisk A/S’s share was trading at $56.72 as of October 15th. NVO’s trailing and forward P/E were 14.98 and 14.08, respectively according to Yahoo Finance. Novo Nordisk A/S represents a compelling long-term growth […]